| Vital Vision Pllc | |
|
270 W Kagy Blvd Ste B, Bozeman, MT 59715-6055 | |
| (406) 404-1666 | |
| (406) 404-1885 |
| Full Name | Vital Vision Pllc |
|---|---|
| Type | Facility |
| Speciality | Optometrist |
| Location | 270 W Kagy Blvd Ste B, Bozeman, Montana |
| Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1962024125 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | (* (Not Available)) | Primary |
| Provider Name | Sarah Elizabeth Hill |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1952475790 PECOS PAC ID: 7911098173 Enrollment ID: I20071030000309 |
News Archive
The clinical trial for Duchenne muscular dystrophy (DMD) tests the safety and effectiveness of a therapy that was developed over two decades by scientists at the University of North Carolina Chapel Hill's School of Medicine and the University of Pittsburgh.
A week after the health overhaul cleared Congress, a business lobby that opposed the plan is now regrouping to shape its implementation and exact political retribution on supporters, The Wall Street Journal reports. "The U.S. Chamber of Commerce is planning a broad effort to blunt the health overhaul by trying to shape its regulatory language and spending heavily to unseat vulnerable Democrats who voted for it."
The pharmaceutical industry finds itself facing a rapidly changing future in light of the health care bill and the evolving pharmaceutical marketplace. There's never been a time when demand has been so intense for the most accurate and up-to-date information about the pharmaceutical industry, especially pharmaceutical competitive intelligence.
Theraclone Sciences, Inc., a therapeutic antibody discovery and development company, today announced positive top-line data from its Phase 1 trial of TCN-032, a broadly protective, fully human monoclonal antibody, being developed for the treatment of influenza A infections.
› Verified 3 days ago
| Provider Name | Cody Philip Blom |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1265026033 PECOS PAC ID: 6608282546 Enrollment ID: I20210301002618 |
News Archive
The clinical trial for Duchenne muscular dystrophy (DMD) tests the safety and effectiveness of a therapy that was developed over two decades by scientists at the University of North Carolina Chapel Hill's School of Medicine and the University of Pittsburgh.
A week after the health overhaul cleared Congress, a business lobby that opposed the plan is now regrouping to shape its implementation and exact political retribution on supporters, The Wall Street Journal reports. "The U.S. Chamber of Commerce is planning a broad effort to blunt the health overhaul by trying to shape its regulatory language and spending heavily to unseat vulnerable Democrats who voted for it."
The pharmaceutical industry finds itself facing a rapidly changing future in light of the health care bill and the evolving pharmaceutical marketplace. There's never been a time when demand has been so intense for the most accurate and up-to-date information about the pharmaceutical industry, especially pharmaceutical competitive intelligence.
Theraclone Sciences, Inc., a therapeutic antibody discovery and development company, today announced positive top-line data from its Phase 1 trial of TCN-032, a broadly protective, fully human monoclonal antibody, being developed for the treatment of influenza A infections.
› Verified 3 days ago
| Provider Name | Arianna Thereseschabauer Lemay |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1508436627 PECOS PAC ID: 0244625325 Enrollment ID: I20220811000323 |
News Archive
The clinical trial for Duchenne muscular dystrophy (DMD) tests the safety and effectiveness of a therapy that was developed over two decades by scientists at the University of North Carolina Chapel Hill's School of Medicine and the University of Pittsburgh.
A week after the health overhaul cleared Congress, a business lobby that opposed the plan is now regrouping to shape its implementation and exact political retribution on supporters, The Wall Street Journal reports. "The U.S. Chamber of Commerce is planning a broad effort to blunt the health overhaul by trying to shape its regulatory language and spending heavily to unseat vulnerable Democrats who voted for it."
The pharmaceutical industry finds itself facing a rapidly changing future in light of the health care bill and the evolving pharmaceutical marketplace. There's never been a time when demand has been so intense for the most accurate and up-to-date information about the pharmaceutical industry, especially pharmaceutical competitive intelligence.
Theraclone Sciences, Inc., a therapeutic antibody discovery and development company, today announced positive top-line data from its Phase 1 trial of TCN-032, a broadly protective, fully human monoclonal antibody, being developed for the treatment of influenza A infections.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Vital Vision Pllc 270 W Kagy Blvd Ste B, Bozeman, MT 59715-6055 Ph: (406) 404-1666 | Vital Vision Pllc 270 W Kagy Blvd Ste B, Bozeman, MT 59715-6055 Ph: (406) 404-1666 |
News Archive
The clinical trial for Duchenne muscular dystrophy (DMD) tests the safety and effectiveness of a therapy that was developed over two decades by scientists at the University of North Carolina Chapel Hill's School of Medicine and the University of Pittsburgh.
A week after the health overhaul cleared Congress, a business lobby that opposed the plan is now regrouping to shape its implementation and exact political retribution on supporters, The Wall Street Journal reports. "The U.S. Chamber of Commerce is planning a broad effort to blunt the health overhaul by trying to shape its regulatory language and spending heavily to unseat vulnerable Democrats who voted for it."
The pharmaceutical industry finds itself facing a rapidly changing future in light of the health care bill and the evolving pharmaceutical marketplace. There's never been a time when demand has been so intense for the most accurate and up-to-date information about the pharmaceutical industry, especially pharmaceutical competitive intelligence.
Theraclone Sciences, Inc., a therapeutic antibody discovery and development company, today announced positive top-line data from its Phase 1 trial of TCN-032, a broadly protective, fully human monoclonal antibody, being developed for the treatment of influenza A infections.
› Verified 3 days ago
Sather Eye Clinic And Optical, P.c. Optometrist Medicare: Medicare Enrolled Practice Location: 1727 W College St, Bozeman, MT 59715 Phone: 406-587-9610 Fax: 406-587-8369 | |
Bridger Eyecare Optometrist Medicare: Medicare Enrolled Practice Location: 113 E Oak St Ste 2c, Bozeman, MT 59715 Phone: 406-587-2020 Fax: 844-965-9460 | |
N/a Optometrist Medicare: Medicare Enrolled Practice Location: 280 W Kagy Blvd, Suite B, Bozeman, MT 59715 Phone: 406-522-8888 Fax: 406-586-8792 | |
Sarah Q Kirkpatrick, OD Optometrist Medicare: Medicare Enrolled Practice Location: 1425 W Main St, Suite B, Bozeman, MT 59715 Phone: 406-586-2173 Fax: 406-586-3603 | |
Vance Thompson Vision Mt Prof Llc Optometrist Medicare: Medicare Enrolled Practice Location: 1925 N 22nd Ave, Bozeman, MT 59718 Phone: 877-522-3937 | |
Ms. Andria Ernestine Weber, O.D. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 2505 Catron St, Bozeman, MT 59718 Phone: 406-556-9032 | |
Kelsey Long Sykes, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 1425 W Main St Unit B, Bozeman, MT 59715 Phone: 406-586-2173 Fax: 406-586-3603 |